Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Scharf L, Scheid JF, Lee JH, West AP Jr, Chen C, Gao H, Gnanapragasam PN, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ.

Cell Rep. 2014 May 8;7(3):785-95. doi: 10.1016/j.celrep.2014.04.001. Epub 2014 Apr 24.

2.

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC.

Cell. 2013 Mar 28;153(1):126-38. doi: 10.1016/j.cell.2013.03.018.

3.

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.

Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77. doi: 10.1073/pnas.1217207109. Epub 2012 Oct 30.

4.

Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.

Hur EM, Patel SN, Shimizu S, Rao DS, Gnanapragasam PN, An DS, Yang L, Baltimore D.

Blood. 2012 Nov 29;120(23):4571-82. doi: 10.1182/blood-2012-04-422303. Epub 2012 Oct 11.

5.

Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ.

Science. 2011 Dec 2;334(6060):1289-93. doi: 10.1126/science.1213782. Epub 2011 Oct 27.

6.

Single-chain Fv-based anti-HIV proteins: potential and limitations.

West AP Jr, Galimidi RP, Gnanapragasam PN, Bjorkman PJ.

J Virol. 2012 Jan;86(1):195-202. doi: 10.1128/JVI.05848-11. Epub 2011 Oct 19.

7.

Designed oligomers of cyanovirin-N show enhanced HIV neutralization.

Keeffe JR, Gnanapragasam PN, Gillespie SK, Yong J, Bjorkman PJ, Mayo SL.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14079-84. doi: 10.1073/pnas.1108777108. Epub 2011 Jul 28.

8.

A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity.

Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ.

AIDS. 2010 Jul 17;24(11):1633-40. Erratum in: AIDS. 2010 Oct 23;24(16):2601.

9.

Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents.

West AP Jr, Galimidi RP, Foglesong CP, Gnanapragasam PN, Klein JS, Bjorkman PJ.

J Virol. 2010 Jan;84(1):261-9. doi: 10.1128/JVI.01528-09.

10.

Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP Jr, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7385-90. doi: 10.1073/pnas.0811427106. Epub 2009 Apr 16.

11.

Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency.

West AP Jr, Galimidi RP, Foglesong CP, Gnanapragasam PN, Huey-Tubman KE, Klein JS, Suzuki MD, Tiangco NE, Vielmetter J, Bjorkman PJ.

J Virol. 2009 Jan;83(1):98-104. doi: 10.1128/JVI.01564-08. Epub 2008 Oct 22.

Supplemental Content

Loading ...
Support Center